The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on Hughes et al. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS). J. Clin. Med. 2022, 11, 5158

Detalles Bibliográficos
Autores principales: Mistry, Pramod K., Kishnani, Priya S., Balwani, Manisha, Charrow, Joel M., Hull, Judy, Weinreb, Neal J., Cox, Timothy M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10179580/
https://www.ncbi.nlm.nih.gov/pubmed/37176709
http://dx.doi.org/10.3390/jcm12093269

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10179580/
https://www.ncbi.nlm.nih.gov/pubmed/37176709
http://dx.doi.org/10.3390/jcm12093269

Ejemplares similares